Summary
Boston Scientific Corporation reported a significant net loss of $3.578 billion for the second quarter of 2012, primarily driven by a substantial $3.602 billion goodwill impairment charge related to its EMEA reporting unit. This impairment reflects a reassessment of future growth prospects in the European market due to macroeconomic factors. Excluding this charge and other one-time items, the company's adjusted net income was $239 million, or $0.17 per share, reflecting underlying operational performance. Net sales for the quarter decreased by 7% year-over-year to $1.828 billion, impacted by currency headwinds and divestitures, though constant currency sales showed a more moderate 5% decline. Key business segments like Endoscopy and Peripheral Interventions showed positive growth, while Interventional Cardiology and Cardiac Rhythm Management experienced sales declines. The company continues to execute on strategic initiatives, including product development and integration of recent acquisitions like Cameron Health, Inc. Despite the reported net loss, operating cash flow remained strong, providing funds for share repurchases and strategic investments. Management highlighted ongoing efforts in restructuring and cost optimization to improve operational effectiveness and competitiveness. Investors should closely monitor the impact of macroeconomic conditions on international sales, the performance of newly launched products, and the ongoing risk of potential future goodwill impairments in other reporting units.
Financial Highlights
50 data points| Revenue | $1.83B |
| Cost of Revenue | $578.00M |
| Gross Profit | $1.25B |
| SG&A Expenses | $648.00M |
| Operating Expenses | $4.84B |
| Operating Income | -$3.59B |
| Interest Expense | $64.00M |
| Net Income | -$3.58B |
| EPS (Basic) | $-2.51 |
| EPS (Diluted) | $-2.51 |
| Shares Outstanding (Basic) | 1.42B |
| Shares Outstanding (Diluted) | 1.42B |
Key Highlights
- 1Reported a net loss of $3.578 billion for Q2 2012, largely due to a $3.602 billion goodwill impairment charge for the EMEA reporting unit.
- 2Adjusted net income (excluding impairment charges and other items) was $239 million, or $0.17 per share, indicating underlying operational profitability.
- 3Net sales decreased 7% to $1.828 billion in Q2 2012 compared to Q2 2011; constant currency sales decreased 5%.
- 4Acquisition of Cameron Health, Inc. completed in June 2012 for potential total consideration of over $1.3 billion, focused on the subcutaneous implantable cardioverter defibrillator technology.
- 5Strong operating cash flow of $619 million for the first half of 2012, enabling share repurchases and strategic investments.
- 6Gross profit margin improved to 68.4% in Q2 2012 from 65.2% in Q2 2011, driven by the higher-margin PROMUS® Element™ stent system and cost reductions.
- 7Significant litigation accrual of $375 million as of June 30, 2012, reflecting ongoing legal matters.